Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema

Exclusion criteria

• ✕. Treatment naïve group (Part B), any IVT anti-VEGF treatments in the study eye are exclusionary regardless of the time interval since injection.
• ✕. Previously treated group (Part A and B), subjects in the previously treated group are excluded if they meet any of the below criteria for the study eye at screening:
• ✕. Subject has received less than 3 anti-VEGF injections since treatment initiation (at least three injections must have been received for eligibility).
• ✕. Time interval between the first anti-VEGF injection and screening is more than 40 weeks.
• ✕. Last injection with ranibizumab or bevacizumab within 4 weeks prior to screening.
• ✕. Last injection with aflibercept within 8 weeks prior to screening.
• ✕. Last injection with faricimab or brolucizumab within 12 weeks prior to screening.
• ✕. Prior treatment with SUSVIMO (Port Delivery System) implant is exclusionary.